The clinical benefit and cost effectiveness of a gastrointestinal care bundle for patients undergoing pelvic chemoradiotherapy

The clinical benefit and cost effectiveness of a gastrointestinal care bundle for patients undergoing pelvic chemoradiotherapy: a randomised controlled pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN78348850

Enrollment

Registered

2014-07-10

Start date

2012-12-06

Completion date

Unknown

Last updated

2020-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Cancer

Interventions

Gastrointestinal Care Bundle, Nutritional intervention and detecting and treating lactose intolerance, small bowel bacterial overgrowth and bile acid malabsorption Study Entry : Singl

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Age =18 years 2. Histologically confirmed cervical or bladder cancer 3. Patients undergoing potentially curative chemoradiotherapy 4. Ability to give informed consent to participate

Exclusion criteria

Exclusion criteria: 1. Age <18 years 2. No histological diagnosis of cervical or bladder cancer 3. Patients unable to complete patient-reported questionnaires 4. Unable to give informed consent 5. Pre-existing GI disease

Design outcomes

Primary

Measure	Time frame
Gastrointestinal symptoms as determined by CTCAE pelvic symptom questionnaire; Timepoint(s): Immediately post-treatment (week 6)	—

Secondary

Measure	Time frame
Not provided at time of regsitration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026